Publication Name	World Journal of Clinical Cases
Manuscript ID	90743
Country	China

Received	2023-12-12 14:45
Peer-Review Started	2023-12-12 14:45
To Make the First Decision
Return for Revision	2024-01-09 04:43
Revised	2024-01-18 07:53
Second Decision	2024-02-22 02:34
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2024-02-22 03:57
Articles in Press	2024-02-22 03:57
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2024-03-04 09:07
Publish the Manuscript Online	2024-03-12 06:10

ISSN	2307-8960 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Oncology
Manuscript Type	Case Report
Article Title	Advanced cervix cancer patient with chemotherapy-induced grade IV myelosuppression achieved complete remission with cadonilimab: A case report
Manuscript Source	Unsolicited Manuscript
All Author List	Rui Zhu, Tian-Ze Chen, Meng-Ting Sun and Chun-Rong Zhu
ORCID	Author(s) ORCID Number Chun-Rong Zhu http://orcid.org/0000-0002-9069-7897
Funding Agency and Grant Number
Corresponding Author	Chun-Rong Zhu, DPhil, PhD, Associate Professor, Chief Doctor, Department of Oncology, The First Affiliated Hospital of Soochow University, No. 188 Shizi Street, Gusu District, Suzhou 215000, Jiangsu Province, China. zcr050311@163.com
Key Words	Cadonilimab; Complete response; Bispecific antibodies; Recurrent or metastatic cervical cancer; Programmed death protein 1; Cytotoxic T-lymphocyte-associated antigen-4; Case report
Core Tip	Advanced metastatic cervical cancer (MCC) has a poor prognosis and a low survival rate. The emergence of bispecific antibodies offers a novel treatment option for patients with MCC. Cadonilimab is a tetravalent bispecific antibody designed to simultaneously block the programmed death protein 1 (PD-1) and cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) pathways while substantially reducing toxicities compared to combination therapy with PD-1 and CTLA-4 antibodies. We report the case of a patient with advanced MCC who achieved a complete response with cadonilimab monotherapy despite chemotherapy-induced grade IV myelosuppression.
Publish Date	2024-03-12 06:10
Citation	Zhu R, Chen TZ, Sun MT, Zhu CR. Advanced cervix cancer patient with chemotherapy-induced grade IV myelosuppression achieved complete remission with cadonilimab: A case report. World J Clin Cases 2024; 12(8): 1510-1516
URL	https://www.wjgnet.com/2307-8960/full/v12/i8/1510.htm
DOI	https://dx.doi.org/10.12998/wjcc.v12.i8.1510

Full Article (PDF)	WJCC-12-1510-with-cover.pdf
CARE Checklist–2016	90743-CARE Checklist (2016).pdf
Manuscript File	90743_Auto_Edited-YJP.docx
Answering Reviewers	90743-Answering reviewers.pdf
Audio Core Tip	90743-Audio core tip.m4a
Conflict-of-Interest Disclosure Form	90743-Conflict-of-interest statement.pdf
Copyright License Agreement	90743-Copyright license agreement.pdf
Signed Consent for Treatment Form(s) or Document(s)	90743-Informed consent statement.pdf
Non-Native Speakers of English Editing Certificate	90743-Language certificate.pdf
Peer-review Report	90743-Peer-review(s).pdf
Scientific Misconduct Check	90743-CrossCheck.png
Scientific Misconduct Check	90743-Bing-Gong ZM-2.png
Scientific Editor Work List	90743-Scientific editor work list.pdf